公开(公告)号：US20210228629A1

公开(公告)日：2021-07-29

申请号：US17050694

申请日：2019-04-26

Applicant: CRISPR THERAPEUTICS AG ,  BAYER HEALTHCARE, LLC

Inventor： Gregory COST

IPC: A61K35/17 ,  C12N15/113 ,  C07K14/715 ,  A61P43/00 ,  C12N15/90

Abstract: The present application relates to compositions and methods for controlled plasma cell depletion, such as for the treatment of various diseases and conditions associated with plasma cells.

公开(公告)号：US11008587B2

公开(公告)日：2021-05-18

申请号：US16928158

申请日：2020-07-14

Applicant: CRISPR THERAPEUTICS AG

Inventor： Alireza Rezania ,  Rebeca Ramos-Zayas

IPC: C12N15/63 ,  C12N15/79 ,  C12N15/85 ,  C07H21/04 ,  C12N5/074 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  C12N5/0735 ,  C07K14/74 ,  C12N5/071 ,  C07K14/705

Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or component or transcriptional regulator of the MHC-I or MHC-II complex, at least one genetic modification that increases the expression of at least one polynucleotide that encodes a tolerogenic factor, and optionally at least one genetic modification that increases or decreases the expression of at least one gene that encodes a survival factor.

公开(公告)号：US20210079347A1

公开(公告)日：2021-03-18

申请号：US17012957

申请日：2020-09-04

Applicant: CRISPR Therapeutics AG

Inventor： Jonathan Alexander Terrett ,  Demetrios Kalaitzidis ,  Hanspeter Waldner

IPC: C12N5/0783 ,  C12N15/113 ,  C12N9/22 ,  C07K14/705

Abstract: A T cell bank comprising genetically engineered T cells having one or more of the following features as compared to the non-engineered T cell counterparts: (a) enhanced expansion capacity in culture, (b) enhanced proliferation capacity, (c) reduced apoptosis, and (d) enhanced activation frequencies. Such genetically engineered T cells may comprise (i) a mutated gene involved in cell self-renewal; (ii) a disrupted gene involved in apoptosis; (iii) a disrupted gene involved in regulation of T cell exhaustion; or (iv) a combination of any one of (i)-(iii).

公开(公告)号：US20210008161A1

公开(公告)日：2021-01-14

申请号：US16904493

申请日：2020-06-17

Applicant: CRISPR THERAPEUTICS AG

Inventor： Sanjay D'Souza ,  Jason West

IPC: A61K38/17 ,  C12N15/86 ,  C12N7/00 ,  C12N15/11 ,  C12N9/22 ,  C12N5/0783 ,  A61K35/17 ,  C12N5/0789 ,  A61P37/06 ,  A61P7/06

Abstract: The disclosure features methods of increasing repair of a DNA double stranded break (DSB) in a target gene by the homology-directed repair (HDR) pathway. The disclosure also features compositions for use in the methods.

公开(公告)号：US20200330518A1

公开(公告)日：2020-10-22

申请号：US16923249

申请日：2020-07-08

Applicant: CRISPR Therapeutics AG

Inventor： Jonathan Alexander Terrett ,  Demetrios Kalaitzidis ,  Lawrence Klein

IPC: A61K35/17 ,  C12N15/62 ,  C12N15/63 ,  A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C12N15/10

Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.

公开(公告)号：US10729725B2

公开(公告)日：2020-08-04

申请号：US16435173

申请日：2019-06-07

Applicant: CRISPR Therapeutics AG

Inventor： Jonathan Alexander Terrett ,  Demetrios Kalaitzidis ,  Lawrence Klein

IPC: A61K35/17 ,  C12N15/62 ,  C12N15/63 ,  A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C12N15/10 ,  C12N15/90

Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.

公开(公告)号：US20190185849A1

公开(公告)日：2019-06-20

申请号：US16312676

申请日：2017-06-29

Applicant: CRISPR Therapeutics AG

Inventor： Ante Sven Lundberg ,  Samarth Kulkarni ,  Lawrence Klein ,  Hari Kumar Padmanabhan

IPC: C12N15/11 ,  A61K48/00 ,  A61K35/407 ,  A61K31/7088 ,  A61K38/46 ,  A61K9/00 ,  C12N7/00 ,  C12N9/22

CPC classification number: C12N15/11 ,  A61K9/0019 ,  A61K31/7088 ,  A61K35/407 ,  A61K38/465 ,  A61K48/0066 ,  C12N7/00 ,  C12N9/22 ,  C12N15/1136 ,  C12N2310/20 ,  C12N2750/14143 ,  C12N2800/80

Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with ANGPTL4 whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of ANGPTL4 gene in a cell by genome editing.

公开(公告)号：US20190160186A1

公开(公告)日：2019-05-30

申请号：US16312630

申请日：2017-06-22

Applicant: CRISPR Therapeutics AG

Inventor： Ante Sven Lundberg ,  Samarth Kulkarni ,  Lawrence Klein ,  Hari Kumar Padmanabhan

IPC: A61K48/00 ,  C12N15/90 ,  A61K35/30 ,  C12N5/079 ,  C12N5/0793 ,  C12N15/11 ,  C12N9/22 ,  C07K14/47 ,  A61P25/28

Abstract: The present application provides materials and methods for treating a patient with one or more condition associated with FXN whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of FXN gene in a cell by genome editing.

公开(公告)号：US20190076551A1

公开(公告)日：2019-03-14

申请号：US16084531

申请日：2017-03-16

Applicant: CRISPR Therapeutics AG

Inventor： Roman Lvovitch Bogorad ,  Chad Albert Cowan ,  Ante Sven Lundberg

IPC: A61K48/00 ,  A61K9/00 ,  C12N5/0775 ,  C12N5/071

Abstract: Materials and methods for treating a patient with hereditary hemochromatosis (HHC), both ex vivo and in vivo, and materials and methods for modulating the expression, function, or activity of a haemochromatosis (HFE) gene in a cell by genome editing.

公开(公告)号：US12203110B2

公开(公告)日：2025-01-21

申请号：US16982433

申请日：2019-03-19

Applicant: CRISPR THERAPEUTICS AG ,  BAYER HEALTHCARE LLC

Inventor： Andre Cohnen ,  Moritz Schmidt ,  Wayne Coco ,  Michael Biag Gamalinda ,  Ashish Gupta ,  Christian Pitzler ,  Florian Richter ,  Jan Tebbe ,  Christopher Cheng ,  Ryo Takeuchi ,  Caroline W. Reiss

IPC: C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  C12N15/90

Abstract: Aspects of this invention, inter alia, relate to novel systems for targeting, editing or manipulating DNA in a cell, using novel synthetic RNA-guided nucleases (sRGNs). The sRGNs are derived from wildtype or parental small type II CRISPR Cas9 endonucleases.